{"schema_version":"1","generated_at":"2026-11-04T17:48:07.939Z","data_as_of":null,"url":"https://www.findmykol.com/kol/yubin-kang","json_url":"https://www.findmykol.com/kol/yubin-kang/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"yubin-kang","name":"Yubin Kang","credential":"MD","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Hematology","therapeutic_areas":["Hematology"],"city":"Oklahoma City","state":"OK","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"}},"identifiers":{"npi":"1205046927","orcid":"0000-0001-6678-8732","openalex":"A5008453908"},"summary":"Yubin Kang is a Hematology physician. OpenAlex indexes 173 publications with 4,725 citations (h-index 35); ClinicalTrials.gov lists 2 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Hematology"]},"scholarship":{"works_count":173,"cited_by_count":4725,"h_index":35,"latest_activity_year":2026,"source":"works"},"trials":{"count":2,"shown":3,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT06822972","title":"HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM","phase":"PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"Duke University","source_url":"https://clinicaltrials.gov/study/NCT06822972","trial_url":"https://www.findmykol.com/trial/NCT06822972"},{"nct":"NCT05397132","title":"Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies","status":"COMPLETED","role":"Overall official","sponsor":"Duke University","source_url":"https://clinicaltrials.gov/study/NCT05397132","trial_url":"https://www.findmykol.com/trial/NCT05397132"},{"nct":"NCT02757326","title":"ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma","phase":"PHASE1/PHASE2","status":"TERMINATED","role":"Overall official","sponsor":"RedHill Biopharma Limited","source_url":"https://clinicaltrials.gov/study/NCT02757326","trial_url":"https://www.findmykol.com/trial/NCT02757326"}],"source":"trials"},"payments":{"company_count":6,"program_years":{"first":2021,"last":null},"rows_total":21,"shown":3,"withheld":18,"rows":[{"payer":"Janssen","program_year":2025,"amount_usd":95452.37,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1205046927"},{"payer":"Karyopharm","program_year":2025,"amount_usd":90788.21,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1205046927"},{"payer":"Regeneron","program_year":2025,"amount_usd":85990.38,"payment_count":26,"source_url":"https://openpaymentsdata.cms.gov/search?query=1205046927"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1205046927","source":"payments"},"prescribing":{"data_year":2024,"areas_total":2,"areas_shown":2,"areas":[{"area":"Cancer & immunology","share_pct":92.6,"classes_total":2,"classes":[{"class":"Thalidomide Analog","setting":"prescribed","share_pct":74.8,"drugs":[{"name":"Lenalidomide","share_pct":57},{"name":"Revlimid","share_pct":30.6},{"name":"Pomalyst","share_pct":12.4}],"max_beneficiaries":null},{"class":"Proteasome Inhibitor","setting":"prescribed","share_pct":17.8,"drugs":[{"name":"Ninlaro","share_pct":100}],"max_beneficiaries":null}]},{"area":"Dermatology","share_pct":7.4,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":7.4,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"mixed","data_year":2024,"office_pct":59.4,"facility_pct":40.6},"source":"medicare"},"funding":{"award_count":2,"fiscal_years":{"first":2025,"last":2026},"rows_total":3,"shown":3,"withheld":0,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"R01CA293516","title":"Phase I/II clinical trial of in-house BCMA CAR T-cell therapy and opaganib in ultrahigh risk multiple myeloma","fiscal_year":2026,"amount_usd":"628602","organization":"UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR","source_url":"https://reporter.nih.gov/quickSearch/R01CA293516"},{"project":"U01AI187020","title":"Thioredoxin derivatives for radiation mitigation","fiscal_year":2026,"amount_usd":"489684","organization":"UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR","source_url":"https://reporter.nih.gov/quickSearch/U01AI187020"},{"project":"U01AI187020","title":"Thioredoxin derivatives for radiation mitigation","fiscal_year":2025,"amount_usd":"322305","organization":"UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR","source_url":"https://reporter.nih.gov/quickSearch/U01AI187020"}],"source":"grants"},"contact":{"address_1":"800 NE 10TH ST STE B","city":"Oklahoma City","state":"OK","zip":"731045418","phone":"405-271-4022","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1205046927","source":"identity"},"similar":[{"name":"Joseph Antin","slug":"joseph-antin","institution":"Harvard University","specialty":"Hematology","url":"https://www.findmykol.com/kol/joseph-antin","json_url":"https://www.findmykol.com/kol/joseph-antin/profile.json"},{"name":"Scott Kaufmann","slug":"scott-kaufmann","institution":"Mayo Clinic College of Medicine","specialty":"Hematology","url":"https://www.findmykol.com/kol/scott-kaufmann","json_url":"https://www.findmykol.com/kol/scott-kaufmann/profile.json"},{"name":"Ruben Mesa","slug":"ruben-mesa","institution":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/ruben-mesa","json_url":"https://www.findmykol.com/kol/ruben-mesa/profile.json"},{"name":"Jaroslaw Maciejewski","slug":"jaroslaw-maciejewski","institution":"Cleveland Clinic","specialty":"Hematology","url":"https://www.findmykol.com/kol/jaroslaw-maciejewski","json_url":"https://www.findmykol.com/kol/jaroslaw-maciejewski/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":18}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2026-03-25","provider_certified":"2026-03-25","collected_at":"2026-11-04T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}